Clinical Trial Update: Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating liraglutide plus megestrol acetate for endometrial atypical hyperplasia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Endometrial Hyperplasia
• Infertility
• Obesity

Drugs mentioned

• Megestrol acetate (Megace) (megestrol acetate)
• liraglutide (liraglutide)

Snippet

Sponsor: Xiaojun Chen | Conditions: Atypical Endometrial Hyperplasia, Obese | Phase 2, Phase 3 | Status: WITHDRAWN